Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.40 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | ABL2 | P42684 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 7/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30582598 | 1.00 | SRC (0.40) | SRCEGFRABL1ABL2BTK | |
| SCHEMBL26108691 | 0.96 | SRC (0.41) | SRCEGFRABL1ABL2BTK | |
| SCHEMBL30582586 | 0.96 | SRC (0.41) | SRCEGFRABL1ABL2BTK | |
| SCHEMBL26105368 | 0.96 | SRC (0.40) | SRCEGFRABL1ABL2BTK | |
| SCHEMBL30582573 | 0.96 | SRC (0.40) | SRCEGFRABL1ABL2BTK | |
| SCHEMBL30582498 | 0.89 | BTK (0.50) | EGFRBTKRET | |
| SCHEMBL26108116 | 0.87 | SRC (0.50) | SRCEGFRABL1ABL2BTK | |
| SCHEMBL30582555 | 0.87 | SRC (0.50) | SRCEGFRABL1ABL2BTK | |
| SCHEMBL26587296 | 0.86 | BTK (0.47) | EGFRBTKRET | |
| SCHEMBL26587204 | 0.85 | CYP3A4 (0.40) | EGFRBTKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024091370-A1 | 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |